These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25282155)

  • 1. Independent factors for prediction of poor outcomes in patients with febrile neutropenia.
    Günalp M; Koyunoğlu M; Gürler S; Koca A; Yeşilkaya I; Öner E; Akkaş M; Metin Aksu N; Demirkan A; Polat O; Elhan AH
    Med Sci Monit; 2014 Oct; 20():1826-32. PubMed ID: 25282155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
    Ahn S; Lee YS; Lim KS; Lee JL
    Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.
    Choi A; Park I; Lee HS; Chung J; Kim MJ; Park YS
    Ann Med; 2022 Dec; 54(1):599-609. PubMed ID: 35175159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
    Ahn S; Lee YS; Chun YH; Kwon IH; Kim W; Lim KS; Kim TW; Lee KH
    Support Care Cancer; 2011 Aug; 19(8):1151-8. PubMed ID: 20552376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.
    Pettit N; Boadu D; Bischof JJ
    Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
    Combariza JF; Lombana M; Pino LE; Arango M
    Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department?
    Chen AY; Gottlieb M; Vilke GM; Coyne C
    J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
    Bhardwaj PV; Emmich M; Knee A; Ali F; Walia R; Roychowdhury P; Clark J; Sridhar A; Lagu T; Loh KP
    Support Care Cancer; 2021 Oct; 29(10):5905-5914. PubMed ID: 33761002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
    Mohindra R; Mathew R; Yadav S; Aggarwal P
    Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients.
    Heo S; Jeon K; Park B; Ko RE; Kim T; Hwang SY; Yoon H; Shin TG; Cha WC; Lee SU
    Am J Emerg Med; 2023 May; 67():90-96. PubMed ID: 36821961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
    Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
    Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
    Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
    Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
    García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
    Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.